You are here: Home » International » News » Companies
Business Standard

Pharma cos leaning on $850,000 therapy to justify super-expensive drugs

An influx of very expensive drugs that offer a one-time cure, such as a hepatitis C therapy from Gilead Sciences, has already stretched state and federal budgets

Reuters  |  San Francisco 

Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive - and effective - new medicines. Spark Therapeutics Inc plans to launch its recently approved Luxturna treatment for an inherited genetic mutation that causes blindness in March. The drug is to be administered only once, by injection, and Spark plans to charge $425,000 per eye, an unprecedented price. But what is grabbing the attention of other drugmakers is not just what might be called an eye-popping price to treat a condition that ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Sat, January 13 2018. 10:14 IST